Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on November 2nd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Price Performance

NASDAQ:BBIO opened at $78.17 on Friday. The business’s 50-day moving average is $69.92 and its two-hundred day moving average is $72.79. BridgeBio Pharma, Inc. has a 12 month low of $62.50 and a 12 month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $353.17 million for the quarter, compared to analyst estimates of $293.47 million. The business’s revenue was up 192.6% on a year-over-year basis. During the same period last year, the firm posted ($0.95) earnings per share. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.55 EPS for the current year.

Insiders Place Their Bets

In other BridgeBio Pharma news, CEO Neil Kumar sold 34,980 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the sale, the chief executive officer directly owned 243,327 shares of the company’s stock, valued at approximately $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares in the company, valued at approximately $8,792,047.95. The trade was a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 56,980 shares of company stock valued at $4,563,699. 14.23% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Silvant Capital Management LLC bought a new stake in shares of BridgeBio Pharma in the 2nd quarter valued at approximately $28,000. Allworth Financial LP acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter valued at approximately $31,000. Root Financial Partners LLC bought a new position in BridgeBio Pharma during the third quarter worth $28,000. SBI Securities Co. Ltd. lifted its stake in BridgeBio Pharma by 55.3% during the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock worth $29,000 after purchasing an additional 157 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BridgeBio Pharma during the second quarter worth $44,000. Institutional investors own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BBIO. Truist Financial lifted their price objective on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Barclays decreased their target price on shares of BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Morgan Stanley raised their price target on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, October 30th. HC Wainwright reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Tuesday, October 6th. Finally, Mizuho boosted their price objective on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Nineteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.